

Bausch Health Companies Inc.  
Form 8-K  
April 30, 2019

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 30, 2019**

**Bausch Health Companies Inc.**

**(Exact name of registrant as specified in its charter)**

**British Columbia, Canada  
(State or other jurisdiction of  
incorporation or organization)**

**001-14956  
(Commission  
File Number)  
2150 St. Elzéar Blvd. West**

**98-0448205  
(I.R.S. Employer  
Identification Number)**

**Laval, Quebec**

**Canada H7L 4A8**

**(Address of Principal Executive Offices) (Zip Code)**

**514-744-6792**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01. Regulation FD Disclosure.**

Bausch Health Companies Inc. (the Company ) is providing a presentation (the AGM Presentation ) on its business to its shareholders at its annual general meeting on April 30, 2019. The AGM Presentation contains substantially the same information as has been previously provided by the Company to investors in other presentations as well as limited new information.

The AGM Presentation is attached as Exhibit 99.1 to this current report on Form 8-K and will be available on the Company's website under the tab Investors Investor Relations Home .

No information on the Company's website is incorporated by reference into this report. The information contained in this Item 7.01 is being furnished, not filed, pursuant to Item 7.01. Accordingly, this information will not be incorporated by reference into any registration statement filed by the Company under the Securities Act, unless specifically identified therein as being incorporated by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits**

<b>Exhibit Number</b>	<b>Description</b>
99.1	AGM Presentation
99.2	Press Release regarding the AGM Presentation, dated April 30, 2019

**EXHIBIT INDEX**

**(d) Exhibits**

<b>Exhibit Number</b>	<b>Description</b>
99.1	<u>AGM Presentation</u>
99.2	<u>Press Release regarding the AGM Presentation, dated April 30, 2019</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BAUSCH HEALTH COMPANIES INC.**

By: /s/ Christina M. Ackermann

Name: Christina M. Ackermann

Title: Executive Vice President and

General Counsel

Date: April 30, 2019